ABT-888 (Veliparib) is a potent inhibitor of both PARP-1 and PARP-2. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.

Veliparib

≥99% by HPLC

ABT-888 (Veliparib) is a potent inhibitor of both PARP-1 and PARP-2 by [3H]NAD+ with Ki of 5.2 nmol/L and 2.9 nmol/L, respectively. ABT-888 inhibited PARP-1 with IC50 of 4.4 nM using BPS Bioscience PARP1 Chemiluminescent Assay Kit (Cat. #80551).

Soluble in DMSO.

White to beige powder.

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

1. Donawho, C. K., et al., Clinical Cancer Research May 2007 13; 2728.
2. Sanchez, E. V., et al., Meeting: 2009 ASCO Annual Meeting. Citation: J Clincal Oncol. 27: 15s, 2009 (suppl; abstr 11028).
3. Liu, SK., et al., Radiother Oncol. 2008 Aug; 88(2): 258-68.

PARP

Inhibitor